Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 555

1.

Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.

Foster JM, Gatalica Z, Lilleberg S, Haynatzki G, Loggie BW.

Ann Surg Oncol. 2009 Jan;16(1):152-8. doi: 10.1245/s10434-008-0206-6. Epub 2008 Nov 8.

PMID:
18998063
2.

Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.

Foster JM, Radhakrishna U, Govindarajan V, Carreau JH, Gatalica Z, Sharma P, Nath SK, Loggie BW.

World J Surg Oncol. 2010 Oct 13;8:88. doi: 10.1186/1477-7819-8-88.

3.

Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma.

Okuda K, Sasaki H, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.

J Cancer Res Clin Oncol. 2008 Oct;134(10):1105-11. doi: 10.1007/s00432-008-0384-4. Epub 2008 Apr 8.

PMID:
18392851
4.

Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer.

Lim KH, Huang MJ, Liu HC, Kuo HT, Tzen CY, Hsieh RK.

Med Oncol. 2007;24(4):388-93.

PMID:
17917087
5.

Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M.

Ann Surg Oncol. 2009 Feb;16(2):463-72. doi: 10.1245/s10434-008-0219-1. Epub 2008 Dec 12.

PMID:
19082859
6.

Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.

Deraco M, Nonaka D, Baratti D, Casali P, Rosai J, Younan R, Salvatore A, Cabras Ad AD, Kusamura S.

Ann Surg Oncol. 2006 Feb;13(2):229-37. Epub 2006 Jan 18.

PMID:
16444562
7.

Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.

Brachtel EF, Iafrate AJ, Mark EJ, Deshpande V.

Diagn Cytopathol. 2007 May;35(5):257-62.

PMID:
17427221
8.

Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.

Murray S, Timotheadou E, Linardou H, Vrettou AV, Kostopoulos I, Skrickova J, Papakostantinou C, Christodoulou C, Pectasides D, Samantas E, Papakostas P, Skarlos DV, Kosmidis P, Fountzilas G.

Lung Cancer. 2006 May;52(2):225-33. Epub 2006 Mar 29.

PMID:
16567021
9.

Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.

Hama T, Yuza Y, Saito Y, O-uchi J, Kondo S, Okabe M, Yamada H, Kato T, Moriyama H, Kurihara S, Urashima M.

Oncologist. 2009 Sep;14(9):900-8. doi: 10.1634/theoncologist.2009-0058. Epub 2009 Sep 2. Erratum in: Oncologist. 2009 Oct;14(10):1050.

10.

Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma.

Bode B, Frigerio S, Behnke S, Senn B, Odermatt B, Zimmermann DR, Moch H.

Mod Pathol. 2006 Apr;19(4):541-7.

11.

Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.

Rena O, Boldorini LR, Gaudino E, Casadio C.

J Surg Oncol. 2011 Nov 1;104(6):701-5. doi: 10.1002/jso.21901. Epub 2011 Mar 21.

PMID:
21437912
12.

Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.

Lee YJ, Park IK, Park MS, Choi HJ, Cho BC, Chung KY, Kim SK, Chang J, Moon JW, Kim H, Choi SH, Kim JH.

J Cancer Res Clin Oncol. 2009 Dec;135(12):1647-54. doi: 10.1007/s00432-009-0611-7. Epub 2009 Jun 11.

PMID:
19517135
13.

Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.

Kalra N, Ashai A, Xi L, Zhang J, Avital I, Raffeld M, Hassan R.

Oncol Rep. 2012 Jun;27(6):1794-800. doi: 10.3892/or.2012.1725. Epub 2012 Mar 15.

PMID:
22426987
14.

Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M.

Ann Surg Oncol. 2007 Oct;14(10):2790-7. Epub 2007 Jul 28.

PMID:
17661150
15.

EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas.

Liu Y, Xu ML, Zhong HH, Heng WJ, Wu BQ.

Pathol Oncol Res. 2008 Dec;14(4):373-9. doi: 10.1007/s12253-008-9113-1. Epub 2008 Nov 5.

PMID:
18985444
16.

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.

Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, Meerzaman D, Hong KM, Mann F, Dracheva T, Fukuoka J, Travis W, Caporaso NE, Harris CC, Jen J.

Clin Cancer Res. 2005 Mar 15;11(6):2106-10. Erratum in: Clin Cancer Res. 2005 Nov 1;11(21):7960-1.

17.

[Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].

Gómez Portilla A, Cendoya I, Muriel J, Olabarria I, Guede N, Moraza N, Fernández E, Martínez de Lecea C, Magrach L, Martín E, Romero E, Aguado I, Valdovinos M, Larrabide I.

Cir Esp. 2007 Feb;81(2):82-6. Spanish.

18.
20.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.

Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH.

J Clin Oncol. 2009 Dec 20;27(36):6237-42. doi: 10.1200/JCO.2009.23.9640. Epub 2009 Nov 16.

PMID:
19917862

Supplemental Content

Support Center